• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

国药集团新冠病毒灭活疫苗（BBIBP-CorV）在医护人员中诱导的体液免疫反应：一项队列研究。

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study.

作者信息

Gómez de la Torre Juan C, Cáceres-DelAguila José Alonso, Muro-Rojo Cecilia, De La Cruz-Escurra Nathalia, Copaja-Corzo Cesar, Hueda-Zavaleta Miguel, Arenas Siles Daniella, Benites-Zapata Vicente A

机构信息

Clinical Laboratory Roe, Lima 15076, Peru.

Faculty of Health Sciences, Universidad Privada de Tacna, Tacna 23003, Peru.

出版信息

Trop Med Infect Dis. 2022 Apr 24;7(5):66. doi: 10.3390/tropicalmed7050066.

DOI:10.3390/tropicalmed7050066
PMID:35622693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9145142/
Abstract

Insufficient data have been reported about the effect of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) on the humoral response through time in healthcare workers (HCW). This retrospective cohort studied the information of 252 HCW from a private laboratory, comparing the antibody-mediated response provoked by BBIBP-CorV between HCW previously infected with SARS-CoV-2 (PI) and not previously infected (NPI), employing the Elecsys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody Detection kit at intervals of 21, 90, and 180 days after vaccination. The presence of neutralizing antibodies in HCW 21 days after full vaccination was 100% in PI and 91.60% in NPI. We observed a progressive decrease in antibody levels over time in both groups. Comparing HCW PI with NPI, PI had a 10.9, 14.3, and 8.6-fold higher antibody titer with the Elecsys® anti-SARS-CoV-2 S at 21 (p < 0.001), 90 (p< 0.001) and 180 days (p < 0.001) respectively, compared to NPI. Using the percent of signal inhibition (PSI) of the antibody neutralization cPass™, HCW PI showed a level of 1.3, 2.0, and 3.1 times more antibodies, at 21 (p < 0.001), 90 (p < 0.001), and 180 days (p < 0.001) respectively, compared to NPI. We determined a progressive decrease in humoral immunity over time, particularly higher in those NPI.

摘要

关于灭活新型冠状病毒疫苗（BBIBP-CorV）对医护人员（HCW）随时间变化的体液免疫反应的影响，所报告的数据不足。这项回顾性队列研究了一家私立实验室252名医护人员的信息，比较了既往感染过新型冠状病毒（PI）和未感染过（NPI）的医护人员接种BBIBP-CorV后抗体介导的反应，在接种疫苗后的21天、90天和180天使用Elecsys®抗新型冠状病毒刺突蛋白（S）和cPass™新型冠状病毒中和抗体检测试剂盒进行检测。完全接种疫苗后21天，PI组医护人员中和抗体的存在率为100%，NPI组为91.60%。我们观察到两组抗体水平均随时间逐渐下降。与NPI组相比，PI组医护人员在21天（p<0.001）、90天（p<0.001）和180天（p<0.001）时，使用Elecsys®抗新型冠状病毒S检测的抗体滴度分别高10.9倍、14.3倍和8.6倍。使用抗体中和cPass™的信号抑制百分比（PSI），PI组医护人员在21天（p<0.001）、90天（p<0.001）和180天（p<0.001）时，抗体水平分别比NPI组高1.3倍、2.0倍和3.1倍。我们确定体液免疫随时间逐渐下降，尤其是在NPI组中下降更为明显。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/90e058007f97/tropicalmed-07-00066-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/fb3d828d0169/tropicalmed-07-00066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/7636cfe4caf7/tropicalmed-07-00066-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/90e058007f97/tropicalmed-07-00066-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/fb3d828d0169/tropicalmed-07-00066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/7636cfe4caf7/tropicalmed-07-00066-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952c/9145142/90e058007f97/tropicalmed-07-00066-g003.jpg

相似文献

1
Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study.国药集团新冠病毒灭活疫苗（BBIBP-CorV）在医护人员中诱导的体液免疫反应：一项队列研究。
Trop Med Infect Dis. 2022 Apr 24;7(5):66. doi: 10.3390/tropicalmed7050066.
2
Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.对有和无SARS-CoV-2感染史的秘鲁医护人员进行间隔7个月的BBIBP-CorV和BNT162b2异源疫苗接种后体液免疫反应的评估。
Vaccines (Basel). 2022 Mar 24;10(4):502. doi: 10.3390/vaccines10040502.
3
Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru.中和抗体作为接种或未接种异源加强剂量疫苗的医护人员疫苗突破性感染预测指标：秘鲁第三波新冠疫情期间的队列研究
Vaccines (Basel). 2023 Feb 15;11(2):447. doi: 10.3390/vaccines11020447.
4
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.随时间推移医护人员中有无接触 SARS-CoV-2 者对 BBIBP-CorV 疫苗的体液免疫反应。
Mol Immunol. 2022 Mar;143:94-99. doi: 10.1016/j.molimm.2022.01.009. Epub 2022 Jan 17.
5
Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.在有和没有SARS-CoV-2感染史且先前已接种两剂BBIBP-CorV加BNT162b2疫苗的医护人员中接种第四剂mRNA-1273后的体液免疫反应。
Vaccines (Basel). 2023 Apr 25;11(5):894. doi: 10.3390/vaccines11050894.
6
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.健康成年人中，BBIBP-CorV（国药）和 BNT162b2（辉瑞-生物科技）疫苗对 SARS-CoV-2 诱导的抗体和 T 细胞应答的比较。
Geroscience. 2021 Oct;43(5):2321-2331. doi: 10.1007/s11357-021-00471-6. Epub 2021 Oct 11.
7
Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.BBIBP-CORV 疫苗加强针针对 SARS-CoV-2 关切变异株的免疫应答。
J Clin Virol. 2022 Jun;150-151:105161. doi: 10.1016/j.jcv.2022.105161. Epub 2022 Apr 12.
8
Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.接种不同类型和剂量的新型冠状病毒2疫苗后疫苗接种后免疫球蛋白G抗体和T细胞免疫反应的评估：一项回顾性队列研究。
Front Med (Lausanne). 2023 Jan 10;9:1092646. doi: 10.3389/fmed.2022.1092646. eCollection 2022.
9
Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.使用同源或异源加强免疫策略，由第三剂BBIBP-CorV（国药集团）和BNT162b2（辉瑞-生物科技公司）疫苗引发的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体和T细胞反应
Vaccines (Basel). 2022 Mar 30;10(4):539. doi: 10.3390/vaccines10040539.
10
Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.与两种新冠病毒灭活疫苗在初级系列接种后 12 个月诱导的中和抗体水平相关的因素。
Front Immunol. 2022 Sep 9;13:967051. doi: 10.3389/fimmu.2022.967051. eCollection 2022.

引用本文的文献

1
Analysis of COVID-19 Incidence and Protective Potential of Persisting IgG Class Antibodies against SARS-CoV-2 Infection in Hospital Staff in Poland.波兰医院工作人员中新冠病毒感染发病率及持续存在的IgG类抗体对严重急性呼吸综合征冠状病毒2感染的保护潜力分析
Vaccines (Basel). 2023 Jul 4;11(7):1198. doi: 10.3390/vaccines11071198.
2
Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru.中和抗体作为接种或未接种异源加强剂量疫苗的医护人员疫苗突破性感染预测指标：秘鲁第三波新冠疫情期间的队列研究
Vaccines (Basel). 2023 Feb 15;11(2):447. doi: 10.3390/vaccines11020447.
3

本文引用的文献

1
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine.第三剂灭活新型冠状病毒疫苗对B细胞和T细胞反应的强劲诱导作用。
Cell Discov. 2022 Feb 1;8(1):10. doi: 10.1038/s41421-022-00373-7.
2
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.随时间推移医护人员中有无接触 SARS-CoV-2 者对 BBIBP-CorV 疫苗的体液免疫反应。
Mol Immunol. 2022 Mar;143:94-99. doi: 10.1016/j.molimm.2022.01.009. Epub 2022 Jan 17.
3
Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina.
One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test.
医护人员接种疫苗一年后的SARS-CoV-2抗刺突总抗体定量纵向随访及与替代中和试验的相关性评估
Vaccines (Basel). 2023 Feb 3;11(2):355. doi: 10.3390/vaccines11020355.
4
Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.同源加强免疫接种灭活疫苗可在医务人员中引起强烈的抗体反应：一项回顾性研究。
Front Immunol. 2023 Feb 3;14:1099629. doi: 10.3389/fimmu.2023.1099629. eCollection 2023.
5
An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines.SARS-CoV-2感染与疫苗血清学的免疫学综述：对mRNA、腺病毒、灭活及蛋白亚单位疫苗的固有免疫和适应性免疫反应
Vaccines (Basel). 2022 Dec 26;11(1):51. doi: 10.3390/vaccines11010051.
6
Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies.罗氏电化学发光法检测抗SARS-CoV-2刺突蛋白抗体在确定疫苗接种后中和抗体方面的效用。
J Clin Virol Plus. 2023 Feb;3(1):100137. doi: 10.1016/j.jcvp.2023.100137. Epub 2023 Jan 11.
7
IgG antibody response by ELISA using Wuhan and Lambda variant antigens in BBIBP-CORV vaccinated health care workers.使用武汉和 Lambda 变异株抗原的 ELISA 法检测 BBIBP-CORV 疫苗接种医护人员的 IgG 抗体反应。
Rev Peru Med Exp Salud Publica. 2022 Jul-Sep;39(3):267-273. doi: 10.17843/rpmesp.2022.393.10875. Epub 2022 Dec 5.
8
Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.宿主对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的保护性免疫与 COVID-19 疫苗诱导的对 SARS-CoV-2 及其变体的免疫。
Viruses. 2022 Nov 17;14(11):2541. doi: 10.3390/v14112541.
对卫星五号疫苗诱导产生的抗体的长期分析：阿根廷图库曼省的一项前瞻性队列研究。
Lancet Reg Health Am. 2022 Feb;6:100123. doi: 10.1016/j.lana.2021.100123. Epub 2021 Nov 20.
4
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.mRNA-1273 新冠疫苗有效性临床试验的免疫相关性分析。
Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.
5
Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection.体液免疫对 SARS-CoV-2 mRNA 疫苗的反应：既往感染的作用。
PLoS One. 2021 Nov 8;16(11):e0259703. doi: 10.1371/journal.pone.0259703. eCollection 2021.
6
Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.接种新冠灭活疫苗后针对 SARS-CoV-2 的动态 B 细胞和 T 细胞应答。
Clin Microbiol Infect. 2022 Mar;28(3):410-418. doi: 10.1016/j.cmi.2021.10.006. Epub 2021 Oct 26.
7
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals.接种BNT162b2疫苗6个月后产生强大的中和抗体反应：一项针对308名健康个体的前瞻性研究。
Life (Basel). 2021 Oct 12;11(10):1077. doi: 10.3390/life11101077.
8
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.健康成年人中，BBIBP-CorV（国药）和 BNT162b2（辉瑞-生物科技）疫苗对 SARS-CoV-2 诱导的抗体和 T 细胞应答的比较。
Geroscience. 2021 Oct;43(5):2321-2331. doi: 10.1007/s11357-021-00471-6. Epub 2021 Oct 11.
9
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
10
Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.塞尔维亚针对新型冠状病毒2（SARS-CoV-2）感染及四种可用SARS-CoV-2疫苗的特异性抗体动力学的前瞻性队列研究及疫苗有效性：3个月中期报告
Vaccines (Basel). 2021 Sep 17;9(9):1031. doi: 10.3390/vaccines9091031.